Creatinine-Responsive DNA Aptamers for Accurate Ion-Resistant Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing techniques for measuring creatinine levels in bodily fluids are not sensitive enough to detect low levels accurately and are hindered by the presence of other molecules such as magnesium, potassium, and calcium, requiring further buffering solutions that decrease accuracy.

Innovation Solution

Development of single-stranded DNA aptamers with specific oligonucleotide sequences, capable of binding creatinine with a dissociation constant between 10−9 and 10−3 M, which can be immobilized on substrates like gold or quartz to form stem-loop structures, altering conductance or fluorescence upon binding, and are insensitive to interfering ions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional measurement techniques are used, then measurement can be performed, but sensitivity is insufficient to detect low levels of creatinine accurately

Engineering Contradiction:
Improvedetection sensitivityVSAvoidmeasurement accuracy
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent employs aptamers with specifically optimized sequences and structures that exhibit enhanced binding affinity to creatinine, achieving dissociation constants in the range of 10^-9 to 10^-6 M. This parameter optimization of the binding molecule enables detection at clinically relevant low concentrations while maintaining accuracy despite the presence of interfering ions.

Inventive Principle:
Principle #35Parameter changes

2Object-affected harmful factors

If buffering solutions are added to handle interfering molecules, then interference from ions like magnesium, potassium, calcium, or sodium can be managed, but measurement accuracy decreases

Engineering Contradiction:
Improveinterference resistanceVSAvoidmeasurement accuracy
Core Design Contradiction:
Object-affected harmful factorsVSMeasurement precision

Solution Approach 1:

The patent uses aptamers as selective intermediary binding molecules that specifically recognize and bind to creatinine with high affinity while exhibiting minimal binding to interfering ions. This selective intermediary approach allows direct measurement in complex biological matrices without requiring buffering solutions, thereby maintaining measurement accuracy while achieving interference resistance.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Ease of operation

If direct measurement without buffering is attempted, then measurement simplicity is improved, but accuracy decreases due to interfering molecules

Engineering Contradiction:
Improvemeasurement simplicityVSAvoidmeasurement accuracy
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The aptamer-based measurement system enables self-service direct measurement by inherently resisting interference from common ions through its selective binding properties. The system requires no external buffering or sample preparation modifications, allowing direct measurement of creatinine in complex biological samples while maintaining both simplicity and accuracy.

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables accurate and direct measurement of creatinine levels in clinical samples without additional buffering, providing sensitivity across a wide range of concentrations and resistance to interfering ions, facilitating diagnosis and treatment of kidney diseases.

Implementation Method 1

the aptamer can be configured to bind the target molecule/analyte with a dissociation constant between about 10−9 and about 10−3 M

Methodology Applied
Scientific EffectMolecular recognition and binding:

Implementation Method 2

The stem region can be configured to be positioned to transform a second conformation into a stem-loop structure of the aptamer, or stem-loop structure into a second conformation when the oligonucleotide sequence binds to the target molecule/analyte

Methodology Applied
Scientific EffectConformational change:

Implementation Method 3

altering conductance or fluorescence upon binding

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Data Source

PatentUS20250277800A1Nucleic acid sequences responsive to creatinine in clinically useful ranges
Publication Date: 2025.09.04 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
  • US20250277800A1 patent drawing
  • US20250277800A1 patent drawing
  • US20250277800A1 patent drawing

AI summary

Aptamers and methods for detecting a target molecule/analyte in a sample are disclosed herein. The aptamer can include a single-stranded deoxyribonucleic acid (DNA) strand that includes an oligonucleotide sequence with bases identical at least about 60% to TAATTGTGGTTCGTGTAAA (SEQ ID NO: 1). The aptamer can be configured to bind the target molecule/analyte with a dissociation constant between about 10−9 and about 10−3 M.